Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Benefit-Cost Analysis | Costing Methods | Government/Law | Health/Medicine | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Economics/Finance | Science/Technology | Global -
ReportPublication 2017DCP3: Injury Prevention and Environmental Health
This report from the World Bank is the seventh volume of the Disease Control Priorities, …
This report from the World Bank is the seventh volume of the Disease Control Priorities, Third Edition (DCP3) series and focuses on injury prevention and environmental health. The burden of death and disability resulting from interpersonal violence, road traffic injuries, unintentional injuries, occupational health risks, and climate and pollution falls disproportionately on low- and middle- income countries. This report examines risk factors and offers an economic analysis of platforms to deliver cost-effective interventions to prevent…
Benefit-Cost Analysis | Costing Methods | Health/Medicine | Culture/Society | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Injuries/Accidents | Environmental Health | Policy/Regulation | Global Governance | Climate/Environment | Economics/Finance | Global -
ArticlePublication 2022Vaccinations versus Lockdowns to Prevent COVID-19 Mortality
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly …
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly available datasets from the Israeli Ministry of Health were used to model the parameters of the pandemic in Israel. The Oxford COVID-19 Government Response Tracker was used for quantitative data on government policies. Data on the Israeli economy were taken from the Central Bureau of Statistics. The models demonstrate that the first lockdown prevented 1022 COVID-19 deaths at the cost…
Costing Methods | Government/Law | Health/Medicine | Decision Theory | Health Outcomes | State-Transition | Decision Analysis | Infectious Diseases | Policy/Regulation | Economics/Finance | Middle East & North Africa -
ArticlePublication 2019Cost-Effectiveness of Latent TB Screening before Immigration to Low-Incidence Countries
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening …
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening for active infections, screening for latent TB infection before immigration is rare. The authors used discrete event simulation to evaluate the cost-effectiveness preimmigration latent TB infection screening for migrants to low-incidence countries. They calculated cost per quality-adjusted life-year gained for migrants from countries with different TB incidences. Their analysis when combined with research on sustainability, acceptability, and program implementation can…
Dynamic Simulation | Government/Law | Health/Medicine | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Global -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Benefit-Cost Analysis | Costing Methods | Government/Law | Health/Medicine | Preferences/Values | Chronic Disease/Risk | Mental Health | Policy/Regulation | Economics/Finance | North America -
ArticlePublication 2017Estimating the Fitness Cost and Benefit of Cefixime Resistance in Neisseria Gonorrhoeae
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more …
Gonorrhoea is one of the most common bacterial sexually transmitted infections in England, and more than half of annual infections occur in men who have sex with men (MSM). As the bacterium has developed resistance to each first-line antibiotic in turn, an improved understanding is needed of fitness benefits and costs of antibiotic resistance to inform control policy and planning. The authors developed a stochastic compartmental model representing the natural history and transmission of cefixime-sensitive…
Government/Law | Health/Medicine | Dynamic Transmission | Decision Analysis | Risk Analysis | Infectious Diseases | Health Systems | Policy/Regulation | Science/Technology | Global -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Costing Methods | Government/Law | Health/Medicine | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Science/Technology | Global -
ReportPublication 2016Economics of Tobacco and Tobacco Control
This report examines the current research and evidence base surrounding the economics of tobacco control—including tobacco …
This report examines the current research and evidence base surrounding the economics of tobacco control—including tobacco use, tobacco growing, manufacturing and trade, tobacco product taxes and prices, and tobacco control policies and other interventions to reduce tobacco use and its consequences. The report was co-produced by the National Cancer Institute and the World Health Organization and is intended to inform tobacco prevention and control programs and policies in countries around the world. There are 17 chapters which can be…
Benefit-Cost Analysis | Costing Methods | Government/Law | Health/Medicine | Chronic Disease/Risk | Policy/Regulation | Food/Agriculture | Global -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Benefit-Cost Analysis | Costing Methods | Government/Law | Health/Medicine | Chronic Disease/Risk | Policy/Regulation | North America